Location: Dublin, Ireland
CO-CHAIRS: Professor Eric Hendrickson (University of Minnesota Medical School) and Dr Jon Moore (Horizon Discovery)
The discovery of the RNA programmable nucleases Cas9 and Cpf1 has greatly facilitated genome editing. The impact of CRISPR technology has been universal, bringing drug discovery to an era of whole genome knockout screens and widely distributed multiplexed in vivo gene editing experiments, as well as moving into the clinic to join ZFN and TALEN powered therapies progressing towards registration.
This unique meeting, being held in Dublin on 17-18 October, will bring leaders in the field together with a wide academic and commercial audience, to explore the new horizons in drug development and therapeutics brought by advancements in CRISPR technology.
What makes this meeting different:
A substantial proportion of the oral programme will be given over to talks selected from submitted abstracts to discuss innovative ideas.
A focus on closing the gap between new developments in CRISPR technology and application in life sciences
This event will be held in association with The Pathologist, media partner to The CRISPR Forum 2017.
Join us to learn about the next wave of CRISPR innovation.
Kilian Huber, Nuffield Department of Medicine, University of Oxford
Andrew Bassett, Wellcome Trust Sanger Institute
Patrick Harrison, University College Cork
Tilmann Buerckstuemmer, Horizon Discovery
Benjamin P Kleinstiver, Massachusetts General Hospital
Linda Popplewell, Royal Holloway, University of London
Tuesday 17 October
Keynote Presentation: CRISPR/Cas9 as a new chapter in the history of gene editing
Eric Hendrickson, University of Minnesota Medical School: Mechanism of gene editing
Therapeutic applications of CRISPR/Cas9
Linda Popplewell, Royal Holloway, University of London: Towards therapy of Duchenne Muscular Dystrophy
Patrick Harrison, University College Cork: Cystic Fibrosis
Tom Henley, Horizon Discovery: TBC
Improvements in CRISPR Technology
Anna Cereseto, University of Trento: Hit and go Cas9 delivered through a lentiviral based self-limiting circuit
Ben Kleinstiver, Massachusetts General Hospital: Hi fidelity Cas9
Wednesday 18 October
Target ID & validation
Carlos le Sage, Horizon Discovery: Getting the best deal - Compare and contrast CRISPR KO, CRISPRi and CRISPRa
Jon Moore, Horizon Discovery: Synthetic lethal target ID
Emma Shanks, The Beatson Institute: Arrayed CRISPR screens
Yaron Galanty, University of Cambridge: Whole genome CRISPR screens
Tilmann Buerkstuemmer, Horizon Discovery: Rapid generation of conditional mutants with CRISPR technology
Applications: The CRISPR revolution in practice
Andrew Bassett, Wellcome Trust Sanger Institute: Using CRISPR to understand miRNA target site regulation
Kilian Huber, Structural Genomics Consortium Oxford University: Target ID via proteomics and CRISPR/Cas9
Jon Moore, Horizon Discovery
CALL FOR PRESENTATIONS
Please complete the call for presentations form.
Areas of particular interest include:
CRISPR Drug Discovery and development
Please be aware, registration does not include accommodation. Below are two nearby hotels within a five-minute walk of the conference venue:
If you are involved in arranging similar educational meetings and conferences, and looking for support, please do let us know by emailing firstname.lastname@example.org